18:10:49 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-13 Kvartalsrapport 2024-Q3
2024-08-21 Kvartalsrapport 2024-Q2
2024-05-15 Kvartalsrapport 2024-Q1
2024-03-28 X-dag ordinarie utdelning CESSA 0.00 DKK
2024-03-27 Årsstämma 2024
2024-02-29 Bokslutskommuniké 2023
2023-11-16 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-12 Kvartalsrapport 2023-Q1
2023-03-24 X-dag ordinarie utdelning CESSA 0.00 DKK
2023-03-23 Årsstämma 2023
2023-02-28 Bokslutskommuniké 2022
2022-11-18 Kvartalsrapport 2022-Q3
2022-11-04 Extra Bolagsstämma 2022
2022-08-19 Kvartalsrapport 2022-Q2
2022-04-19 Kvartalsrapport 2022-Q1
2022-03-18 X-dag ordinarie utdelning CESSA 0.00 DKK
2022-03-17 Årsstämma 2022
2022-02-24 Bokslutskommuniké 2021
2021-11-19 Kvartalsrapport 2021-Q3
2021-08-19 Kvartalsrapport 2021-Q2
2021-04-19 Kvartalsrapport 2021-Q1
2021-03-29 X-dag ordinarie utdelning CESSA 0.00 DKK
2021-03-26 Årsstämma 2021
2021-02-11 Bokslutskommuniké 2020

Beskrivning

LandDanmark
ListaSpotlight DK
SektorHälsovård
IndustriBioteknik
Cessatech är verksamt inom läkemedelsbranschen. Bolaget är specialiserat inom forskning och utveckling av smärtstillande nässpray som vidare används för behandling av akuta smärttillstånd hos barn. Utöver huvudverksamheten erbjuds även tillhörande kringtjänster och relaterade produkter. Verksamheten drivs globalt med störst närvaro inom den nordiska marknaden. Huvudkontoret ligger i Köpenhamn.
2024-07-05 14:31:18

Cessatech A/S, CVR no. 41293055 ("Cessatech" or the "Company") held its extraordinary general meeting on Friday 5 July 2024 at 08:30 (CET) at the Company's address Kanonbådsvej 2, 1437 København K.

The agenda for the general meeting was as follows:

1. ELECTION OF THE CHAIRMAN OF THE MEETING
1. Attorney Anders Rubinstein was elected chairman of the meeting. The chairman of the meeting ascertained that none of the shareholders objected to the legality of the extraordinary general meeting and announced that the extraordinary general meeting had been duly convened and was legal and competent in terms of all items on the agenda. The chairman of the general meeting then informed that based on postal votes and proxies duly received prior to the general meeting a solid support of all proposals on the agenda had been secured in advance of the meeting.

2. PROPOSALS FROM THE BOARD OF DIRECTORS
1. Proposal to elect Anders Dyhr Dombernowsky-Toft as a board member

It was noted that Peter Birk Rasmussen was leaving the Board of Directors. The general meeting unanimously resolved to elect Anders Dyhr Dombernowsky-Toft as a new board member.

1.
2. Clarification of clause 3.1.2 in the Articles of Association

The general meeting unanimously resolved to include a specification of the number of warrants related to a potential new incentive warrant scheme for employees or board members of Cessatech, in article 3.1.2 with the following wording:

"3.2.1 Authorization to issue incentive warrants

The Board of Directors is authorized during the period until 1 January 2027 on one or more occasions to issue 1,936,122 warrants without pre-emptive rights for the Company's shareholders, each conferring the right to subscribe one share of nominal value of DKK 0.20 against cash contribution. Warrants may be issued to board members, members of management and other employees of the Company and its subsidiaries, if any. The specific terms and conditions of the warrants are to be determined by the Board of Directors."

The chairman of the general meeting announced that all the agenda items had been discussed and announced that the extraordinary general meeting had come to an end.

As chairman of the extraordinary general meeting:

__________

Anders Rubinstein
Attorney